Vimarsana
Biggest News Aggregation in the World

Page 8 - Equity Capital Changes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Equity Capital Changes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Equity Capital Changes Today - Breaking & Trending Today

Deposit Insurance Corp to oppose Shinsei's poison pill against SBI -NHK - Vimarsana News

Deposit Insurance Corp to oppose Shinsei's poison pill against SBI -NHK

Government-owned Deposit Insurance Corp of Japan (DICJ) is planning to vote against Shinsei Bank's poison pill defence aimed at blocking SBI Holdings Inc's $1.1 billion bid, public broadcaster NHK reported on Tuesday.

Exclusive-Questions-and-answers site Quora readies IPO-sources - Vimarsana News

Exclusive-Questions-and-answers site Quora readies IPO-sources

U.S. knowledge-sharing website Quora Inc has kicked off preparations for an initial public offering (IPO) in early 2022, according to people familiar with the matter.

Australia's Link to consider Carlyle's fresh $2.1 billion bid, shares soar - Vimarsana News

Australia's Link to consider Carlyle's fresh $2.1 billion bid, shares soar

Australia's Link Administration said on Friday it will consider a fresh A$2.81 billion ($2.08 billion) offer from Carlyle Group, sending the shareholder registry firm's stock up more than 12%.

U.S. bank Moelis, Emirates NBD hired to advise on IPO of Dubai's DEWA - sources - Vimarsana News

U.S. bank Moelis, Emirates NBD hired to advise on IPO of Dubai's DEWA - sources

U.S. investment bank Moelis and Dubai lender Emirates NBD have been hired to advise on the initial public offering (IPO) of Dubai Electricity & Water Authority (DEWA), sources familiar with the matter said.

Novartis cuts uneasy 20-year ties to Roche with $20.7 billion voting stake sale - Vimarsana News

Novartis cuts uneasy 20-year ties to Roche with $20.7 billion voting stake sale

Novartis AG said on Thursday it would sell its nearly one-third voting stake in Roche back to its cross-town rival for $20.7 billion, disentangling the two competitors that had been linked by the investment for more than two decades.